Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Annals of the Rheumatic Diseases

Volumn 74, Issue 6, 2015, Pages 1087-1093

  Mercer, Louise K ^a   Lunt, Mark ^a   Low, Audrey L S ^a   Dixon, William G ^a   Watson, Kath D ^a   Symmons, Deborah P M ^a   Hyrich, Kimme L ^a   Maiden, Nicola ^b   Price, Tom ^c   Hopkinson, Neil ^d   O'Reilly, Sheila ^e   Hordon, Lesley ^f   Griffiths, Ian ^g   Porter, Duncan ^h   Madhok, R ⁱ   Hassell, Andy ^j   Cooper, R G ^k   Choy, Ernest ^l   Walsh, David ^m   Emery, Paul ⁿ   Knight, Susan ^o   Bruce, Ian ^p   Taggart, Allister ^q   Scott, David ^r   Thompson, Paul ^s   McCrae, Fiona ^t   Goodfellow, Rhian ^u   Kitas, George ^v   Jubb, Ronald ^w   Abernethy, Rikki ^x   Green, Sandra ^y   Sanders, Paul ^z   Coulson, Amanda ^aa   Harrison, Bev ^ab   Bukhari, Marwan ^ac   Klimiuk, Peter ^ad   more..

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ANTRIM AREA HOSPITAL   (United Kingdom)

^c ROYAL WOLVERHAMPTON HOSPITALS NHS TRUST   (United Kingdom)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e ROYAL DERBY HOSPITAL   (United Kingdom)

^f Dewsbury and District Hospital   (United Kingdom)

^g FREEMAN HOSPITAL   (United Kingdom)

^h GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

ⁱ GLASGOW ROYAL INFIRMARY   (United Kingdom)

^j HAYWOOD HOSPITAL   (United Kingdom)

^k HOPE HOSPITAL   (United Kingdom)

^l KING S COLLEGE HOSPITAL   (United Kingdom)

^m Kings Mill Centre ^*  (United Kingdom)

ⁿ CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^o MACCLESFIELD DISTRICT GENERAL HOSPITAL   (United Kingdom)

^p MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^q MUSGRAVE PARK HOSPITAL   (United Kingdom)

^r NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^s POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^t QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^u ROYAL GLAMORGAN HOSPITAL   (United Kingdom)

^v RUSSELLS HALL HOSPITAL   (United Kingdom)

^w SELLY OAK HOSPITAL   (United Kingdom)

^x St Helens Hospital   (United Kingdom)

^y WESTON GENERAL HOSPITAL   (United Kingdom)

^z WITHINGTON HOSPITAL   (United Kingdom)

^aa Withybush General Hospital   (United Kingdom)

^ab NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^ac ROYAL LANCASTER INFIRMARY   (United Kingdom)

^ad ROYAL OLDHAM HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ANTIBODY; ADALIMUMAB; ANTIRHEUMATIC AGENT; ETANERCEPT; IMMUNOGLOBULIN G; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; LUNG NEOPLASMS; NEOPLASMS; REGISTER; SMOKING; UNITED KINGDOM;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BREAST NEOPLASMS; COHORT STUDIES; COLORECTAL NEOPLASMS; ETANERCEPT; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOGLOBULIN G; INFLIXIMAB; LUNG NEOPLASMS; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; RISK FACTORS; SMOKING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84932606892     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204851     Document Type: Article

References (30)

1. Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70.
2. Eggermont AM, Schraffordt KH, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg 1996;224:756-64.
3. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. [erratum appears in Nat Med 1999;5:1087]. Nat Med 1999;5:828-31.
4. Knight B, Yeoh GC, Husk KL, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med 2000;192:1809-18.
5. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. [see comment] [erratum appears in JAMA 2006;295:2482]. [Review] [58 refs]. JAMA 2006;295:2275-85.
6. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. [Review] [64 refs]. Ann Rheum Dis 2009;68:1136-45.
7. Askling J, Fahrbach K, Nordstrom B, et al. Cancer risk with tumour necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-30.
8. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009;60:3180-9.
9. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010;12:R5.
10. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. [see comment] [erratum appears in Arthritis Rheum 2006;54:3134]. Arthritis Rheum 2006;54:2757-64.
11. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 2007;56:2886-95.
12. Dreyer L, Mellemkj?r L, Andersen AR, et al. Incidences of overall and site specific cancers in TNFa inhibitor treated patients with rheumatoid arthritis and other arthritides-a follow-up study from the DANBIO Registry. Ann Rheum Dis 2013;72:79-82.
13. Prevoo ML, Van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
14. Ledingham J, Deighton C, on behalf of the British Society for Rheumatology Standards GaAWG. Update on the British Society for Rheumatology guidelines for prescribing TNF{alpha} blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005; 44:157-63.
15. Watson K, Symmons D, Griffiths I, et al. The British Society for Rheumatology biologics register. [Review] [6 refs]. Ann Rheum Dis 2005;64(Suppl 4):iv42-3.
16. Kirwan JR, Reeback JS. Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
17. Office for National Statistics. Cancer Statistics Registrations, England (Series MB1), No. 40, 2009. http://ons.gov.uk/ons/rel/vsob1/cancer-statistics-registrations-england-seriesmb1-/no-40-2009/index.html. 7 Sep 2011 (accessed Feb 2012).
18. Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-26.
19. Mercer LK, Davies R, Galloway JB, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford) 2013;52:91-8.
20. Mellemkjaer L, Linet MS, Gridley G, et al. Rheumatoid arthritis and cancer risk. Eur J Cancer 1996;32A:1753-57.
21. Parikh-Patel A, White RH. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009;20:1001-10.
22. Gridley G, McLaughlin JK, Ekbom A, et al. Incidence of cancer among patients with rheumatoid arthritis. [see comment]. J Natl Cancer Inst 1993;85:307-11.
23. Goldberg JE, Schwertfeger KL. Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. [Review]. Curr Drug Targets 2010;11:1133-46.
24. Su K, Tian Y, Wang J, et al. HIF-1alpha acts downstream of TNF-alpha to inhibit vasodilator-stimulated phosphoprotein expression and modulates the adhesion and proliferation of breast cancer cells. DNA Cell Biol 2012;31:1078-87.
25. Madhusudan S, Foster M, Muthuramalingam SR, et al. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004;10:6528-34.
26. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
27. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001;84:1188-92.
28. Flossmann E, Rothwell PM; British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.[see comment]. [Review] [84 refs]. Lancet 2007;369:1603-13.
29. Raaschou P, Simard JF, Neovius M, et al. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheum 2011;63:1812-22.
30. Dixon WG, Watson KD, Lunt M, et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology biologics register. Arthritis Care Res 2010;62:755-63.